These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1456747)

  • 1. Alpha-tocopherol levels in brain are not altered in Parkinson's disease.
    Dexter DT; Ward RJ; Wells FR; Daniel SE; Lees AJ; Peters TJ; Jenner P; Marsden CD
    Ann Neurol; 1992 Oct; 32(4):591-3. PubMed ID: 1456747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia.
    Maschke M; Gomez CM; Tuite PJ; Konczak J
    Brain; 2003 Oct; 126(Pt 10):2312-22. PubMed ID: 12821507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aluminum deposition in the central nervous system tissues of patients with Parkinson's disease].
    Yasui M; Kihira T; Ota K; Mukoyama M; Adachi K
    Rinsho Shinkeigaku; 1991 Oct; 31(10):1095-8. PubMed ID: 1802464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Gs protein function and G alpha s levels in leukocytes of patients with Parkinson's disease.
    Avissar S; Barki-Harrington L; Herishanu Y; Schreiber G
    Mov Disord; 1997 Mar; 12(2):167-74. PubMed ID: 9087974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
    Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
    Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E exerts selective and differential control over vitamin E concentrations in different areas of mammalian brain.
    Vatassery GT; Lam C; Smith WE; Quach HT
    J Neurosci Res; 2006 Nov; 84(6):1335-42. PubMed ID: 16941498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease.
    Anichtchik OV; Peitsaro N; Rinne JO; Kalimo H; Panula P
    Neurobiol Dis; 2001 Aug; 8(4):707-16. PubMed ID: 11493035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation].
    Dubois B; Hauw JJ; Ruberg M; Serdaru M; Javoy-Agid F; Agid Y
    Rev Neurol (Paris); 1985; 141(3):184-93. PubMed ID: 4001706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
    Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
    Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-tocopherol levels in parkinsonian brains.
    Przedborski S; Jackson-Lewis V; Muthane U
    Ann Neurol; 1993 May; 33(5):560-1. PubMed ID: 8347203
    [No Abstract]   [Full Text] [Related]  

  • 12. [Serum pro-oxidant and antioxidant factors and risk of Parkinson's disease: population study].
    Molina-Arjona JA; de Bustos F; Benito-León J; Jiménez-Jiménez FJ; Rodríguez J; Trincado R; Porta-Etessan J; Vega S; Bermejo F
    Rev Neurol; 1999 Jul 1-15; 29(1):12-5. PubMed ID: 10528302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F; Floridi AG; Floridi A; Buoncristiani U
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
    Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
    Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease.
    Langston JW; Sastry S; Chan P; Forno LS; Bolin LM; Di Monte DA
    Exp Neurol; 1998 Dec; 154(2):684-90. PubMed ID: 9878203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of hepatic vitamin E status in adult patients with liver disease.
    Nagita A; Ando M
    Hepatology; 1997 Aug; 26(2):392-7. PubMed ID: 9252150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2.
    Pham DQ; Plakogiannis R
    Ann Pharmacother; 2005 Dec; 39(12):2065-72. PubMed ID: 16288072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
    Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
    Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short and long latency afferent inhibition in Parkinson's disease.
    Sailer A; Molnar GF; Paradiso G; Gunraj CA; Lang AE; Chen R
    Brain; 2003 Aug; 126(Pt 8):1883-94. PubMed ID: 12805105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.